$HE

S&P upgrades Hawaiian Electric rating on wildfire mitigation By Investing.com

S&P Global Ratings upgraded Hawaiian Electric Industries and subsidiaries to BB- from B+ with a stable outlook, citing declining wildfire risk. The Hawaii Public Utilities Commission approved about $350 million cost recovery for wildfire mitigation over three years. S&P expects funds from operations to debt near 10.5% in 2026, improving above 12% in 2027, and affirmed related debt ratings.

Original reporting
Published Jul 22, 2026, 6:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 22, 2026, 6:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$HE
Bullish
medium confidence
Mentioned
$HE
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$HEBullishMed
01

Why it matters

The upgrade is grounded in reduced wildfire risk assumptions, regulatory validation of mitigation compliance, and an expectation of improving funds-from-operations to debt ratios.

02

Market read

Credit improvement plus regulatory cost recovery details can influence HE’s funding costs and risk premium, though equity impact may be secondary without new earnings or guidance.

03

What to watch

The article highlights cost recovery approval and mitigation spending, but does not quantify remaining exposure, claim outcomes beyond the pre-funded portion, or potential future regulatory changes.

Relevance 7/10Novelty 7/10Timing: post-upgrade credit action by S&P, ahead of next earnings for AI cues

Background

S&P’s action follows Hawaii Public Utilities Commission approval of about $350 million in cost recovery for HECO’s wildfire-mitigation plan investments over three years.

Company-level read

Ticker impact

$HEBullishMedium confidence
Context

S&P upgraded Hawaiian Electric Industries to BB- from B+ citing decreasing wildfire risk and a stable outlook across entities.

Expected impact

Likely modest positive bias for HE credit-sensitive trading, with limited upside unless equity investors reprice materially.

Evidence & confidence

The article is a ratings upgrade with specific regulatory approval and cash-flow/debt metrics, but it is not an earnings or equity guidance print.

Market effects

Supports the broader utility/regulated-asset narrative that wildfire mitigation and cost recovery can improve credit profiles.

Positive for Hawaii regulated utilities’ perceived risk, potentially easing local funding conditions.

Limited, mostly credit-market read-through for similarly exposed utilities.

Counterpoint

A ratings upgrade may not translate into equity rerating if wildfire claim liabilities or regulatory execution risk remain unresolved.

Key entities

  • Hawaiian Electric Industries Inc.

    S&P upgraded its rating to BB- from B+ and kept outlook stable, citing decreasing wildfire risks.

  • Hawaiian Electric Co. Inc. (HECO)

    HECO received affirmed BB rating on senior unsecured debt; recovery rating revised to 2 from 1.

  • Hawaii Public Utilities Commission

    Approved approximately $350 million in cost recovery for wildfire-mitigation plan investments on June 25, 2026.

  • S&P Global Ratings

    Issued the credit upgrade and maintained stable outlook across entities.

Related articles

$HEMed

Hawaiian Electric (HE): Does a $1 Billion Bank IPO Valuation Matter?

Hawaiian Electric Industries (HE) may gain a valuation benchmark for its 9.9% stake in American Savings Bank, with the bank's IPO implying a $1 billion equity value. HE could see approximately $99 million in value from its holding, depending on the IPO's outcome and any share sales. The IPO could provide HE with a more marketable investment and potential financing options, though risks include liquidity constraints and local credit conditions.

$HEMedAI 8/10

Hawaiian Electric (HE) Q2 2026 Earnings Call Transcript

Hawaiian Electric (HE) discussed Q2 2026 results and regulatory updates. The PUC approved recovery of up to $11.5 million of 2025 WMP O&M and $3.9 million annually from 2028. HE expects a phased $170 million base rate increase, with interim decision by Dec 18, 2026. Q2 net income was $123.2 million, or $0.71/share, including a Maui wildfire liability remeasurement reducing expenses by $153.9 million.

$HEMed

HAWAIIAN ELECTRIC INDUSTRIES INC (HE): Results of Operations and Financial Condition

HAWAIIAN ELECTRIC INDUSTRIES INC (HE) filed an SEC Form 8-K — Results of Operations and Financial Condition. HEI Exhibit 99 NEWS RELEASE August 7, 2026 Contact: Mateo Garcia Telephone: (808) 543-7300 Director, Investor Relations E-mail: ir@hei.com HEI REPORTS SECOND QUARTER 2026 RESULTS • One of Hawaiian Electric’s Largest-Ever Energy Solicitations Submitted for PUC Approval in July; Pl

$COINHigh

The SEC Steps In to Ease Crypto’s Path After Big Legislative Loss

The SEC introduced a five-year exemption to securities laws to enable trading of tokenized stocks, following Congress' failure to pass the Clarity Act. This move aims to support digital assets and follows a 48-hour turnaround. Bitcoin and crypto-linked stocks like Coinbase (COIN), Robinhood (HOOD), and Circle (CRCL) saw gains.

$RAREHighAI 9/10

Ultragenyx stock surges 10% on FDA approval for gene therapy

Ultragenyx Pharmaceutical (RARE) shares rose 10% after the FDA approved Fayuvi, a gene therapy for mucopolysaccharidosis type IIIA. This is the first FDA-authorized treatment for this rare pediatric disease. The therapy showed improved cognitive function in clinical trials but carries risks like liver enzyme increases and potential long-term tumor development.

$AZNMed

AstraZeneca Gains as Enhertu Clears England's Value Gate

AstraZeneca's Enhertu gained NHS approval in England for HER2-low metastatic breast cancer treatment, reversing a prior rejection. The company's shares rose 1.3% to $165.04. The drug's cost-effectiveness was not disclosed, but it extends survival by around six months. This approval may expand access in Wales and Northern Ireland, potentially boosting AstraZeneca's revenue.